Voices
Rishabh Jain: FDA Grants Fast Track Designation to DLL3-Targeting ADC Zocilurtatug Pelitecan in epNEC
Rishabh Jain/X

Rishabh Jain: FDA Grants Fast Track Designation to DLL3-Targeting ADC Zocilurtatug Pelitecan in epNEC

Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:

“DLL3 continues to emerge as one of the most important targets in neuroendocrine oncology. The U.S. FDA has granted Fast Track Designation to Zocilurtatug pelitecan (Zoci, ZL-1310), a DLL3-targeting ADC, for previously treated extrapulmonary neuroendocrine carcinomas (epNECs).

Why this matters: epNECs are highly aggressive cancers with no approved post-progression standard therapy

Early Phase 1b/2 data showed:

  • ORR: 38.2%
  • Manageable safety profile
  • Main grade ≥3 TRAE: neutropenia

We are now seeing DLL3 evolve across:

  • ADCs
  • T-cell engagers
  • Radiopharmaceuticals

Could DLL3 become the next major pan-neuroendocrine biomarker platform similar to HER2 or PSMA?”

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

Rishabh Jain

Other articles geaturing Rishabh Jain on OncoDaily.

AIIMS cancer DLL3 DLL3-targeting ADC epNECs FDA HER2 OncoDaily Oncology PSMA Rishabh Jain Zocilurtatug pelitecan